<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在週四更新了其 2025 財年的收益指引。該公司提供的每股收益（EPS）指引為 6.600-6.700，而市場共識預期為 6.610。該公司發佈的收入指引為 4000 億美元-4000 億美元，而市場共識收入預期為 3990 億美元。</p>
<h2>分析師設定新的目標價格</h2>
<ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
<p>CVS 最近成為幾份研究報告的主題。摩根士丹利在 12 月 10 日的研究報告中將 CVS Health 的目標股價從 89.00 美元上調至 93.00 美元，並給予該股票 “超配” 評級。富國銀行在 11 月 13 日的研究報告中將 CVS Health 的目標價格從 103.00 美元下調至 102.00 美元，併為該公司設定了 “超配” 評級。TD Cowen 在 12 月 10 日的研究報告中將 CVS Health 的目標價格從 100.00 美元上調至 105.00 美元，並給予該公司 “買入” 評級。雷蒙德·詹姆斯金融在 10 月 31 日的研究報告中將 CVS Health 的目標價格從 75.00 美元上調至 90.00 美元。最後，沃爾夫研究在 12 月 8 日的研究報告中將 CVS Health 的目標價格從 85.00 美元上調至 100.00 美元，並給予該公司 “跑贏大盤” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat 的數據，CVS Health 的共識評級為 “適度買入”，共識目標價格為 94.67 美元。</p>
<p><strong>獲取我們關於 CVS Health 的最新報告</strong></p>
<h2>CVS Health 股價下跌 0.4%</h2>
<ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
<p>週四，CVS 股票開盤價為 77.95 美元。CVS Health 的 1 年最低價為 43.56 美元，1 年最高價為 85.15 美元。該公司的債務與股本比率為 0.83，流動比率為 0.83，速動比率為 0.63。該公司的 50 日移動平均價格為 79.08 美元，200 日移動平均價格為 72.24 美元。該公司的市值為 989.5 億美元，市盈率為 205.14，市盈增長比率為 0.77，貝塔值為 0.48。</p>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在 10 月 29 日的季度財報中宣佈了其季度收益結果。該藥房運營商報告的每股收益（EPS）為 1.60 美元，超出分析師的共識預期 1.36 美元，超出幅度為 0.24 美元。該公司在本季度的收入為 1028.7 億美元，而市場共識預期為 988.5 億美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司的收入較去年同期增長了 7.8%。去年同期，該公司每股收益為 1.09 美元。CVS Health 已將其 2025 財年的指引設定為 6.550-6.650 EPS。作為一個整體，賣方分析師預測 CVS Health 在當前財年將發佈 5.89 EPS。</p>
<h2>對 CVS Health 的對沖基金看法</h2>
<ul>
<li>現在是買入 Novo Nordisk 股票的時機嗎？</li>
</ul>
<p>幾家對沖基金和其他機構投資者最近買入和賣出了該公司的股票。道富銀行在第三季度將其在 CVS Health 的持股增加了 0.3%。道富銀行目前擁有 58,938,286 股該藥房運營商的股票，價值 4,443,357,000 美元，此前在上個季度購買了 149,701 股。Ameriprise Financial Inc.在第二季度將其在 CVS Health 的持股增加了 5.2%。Ameriprise Financial Inc.目前擁有 7,855,845 股該藥房運營商的股票，價值 541,903,000 美元，此前在上個季度購買了 385,806 股。阿穆迪在第三季度將其在 CVS Health 的持股增加了 95.3%。阿穆迪目前擁有 7,453,980 股該藥房運營商的股票，價值 572,665,000 美元，此前在上個季度購買了 3,637,943 股。威靈頓管理集團在第三季度將其在 CVS Health 的持股增加了 391.6%。威靈頓管理集團目前擁有 6,330,717 股該藥房運營商的股票，價值 477,273,000 美元，此前在上個季度購買了 5,042,816 股。最後，雷蒙德·詹姆斯金融在第二季度將其在 CVS Health 的持股增加了 4.4%。雷蒙德·詹姆斯金融目前擁有 3,191,584 股該藥房運營商的股票，價值 220,155,000 美元，此前在上個季度購買了 133,875 股。80.66% 的股票由機構投資者和對沖基金持有。</p>
<h2>CVS Health 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 CVS Health</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>降息使這三隻收入 ETF 比以往更具吸引力</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>CVS Health 更新了其 2025 財年的收益指引，預計每股收益（EPS）為 6.600-6.700，高於市場共識預期的 6.610，收入指引為 4000 億美元，超過市場共識的 3990 億美元。分析師們已調整了他們的目標價，市場共識評級為 “適度買入”，目標價為 94.67 美元。CVS Health 最近的季度收益超出預期，淨利潤率為 0.12%，股本回報率為 11.45%。機構投資者已增加了對該公司的持股</p>

<p>CVS Health (NYSE:CVS - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus estimate of 6.610. The company issued revenue guidance of $400.0 billion-$400.0 billion, compared to the consensus revenue estimate of $399.0 billion.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在週四更新了其 2025 財年的收益指引。該公司提供的每股收益（EPS）指引為 6.600-6.700，而市場共識預期為 6.610。該公司發佈的收入指引為 4000 億美元-4000 億美元，而市場共識收入預期為 3990 億美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的目標價格</h2>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
</div><p>CVS has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Wells Fargo &amp; Company decreased their price objective on CVS Health from $103.00 to $102.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, November 13th. TD Cowen lifted their target price on CVS Health from $100.00 to $105.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, December 10th. Raymond James Financial upped their price target on CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. Finally, Wolfe Research lifted their price objective on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p>
<div class="lb-trans"><p>CVS 最近成為幾份研究報告的主題。摩根士丹利在 12 月 10 日的研究報告中將 CVS Health 的目標股價從 89.00 美元上調至 93.00 美元，並給予該股票 “超配” 評級。富國銀行在 11 月 13 日的研究報告中將 CVS Health 的目標價格從 103.00 美元下調至 102.00 美元，併為該公司設定了 “超配” 評級。TD Cowen 在 12 月 10 日的研究報告中將 CVS Health 的目標價格從 100.00 美元上調至 105.00 美元，並給予該公司 “買入” 評級。雷蒙德·詹姆斯金融在 10 月 31 日的研究報告中將 CVS Health 的目標價格從 75.00 美元上調至 90.00 美元。最後，沃爾夫研究在 12 月 8 日的研究報告中將 CVS Health 的目標價格從 85.00 美元上調至 100.00 美元，並給予該公司 “跑贏大盤” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat 的數據，CVS Health 的共識評級為 “適度買入”，共識目標價格為 94.67 美元。</p>
</div><p><strong>Get Our Latest Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 CVS Health 的最新報告</strong></p>
</div><h2>CVS Health Trading Down 0.4%</h2>
<div class="lb-trans"><h2>CVS Health 股價下跌 0.4%</h2>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
</div><p>Shares of CVS stock opened at $77.95 on Thursday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The business's fifty day moving average price is $79.08 and its 200 day moving average price is $72.24. The firm has a market capitalization of $98.95 billion, a PE ratio of 205.14, a P/E/G ratio of 0.77 and a beta of 0.48.</p>
<div class="lb-trans"><p>週四，CVS 股票開盤價為 77.95 美元。CVS Health 的 1 年最低價為 43.56 美元，1 年最高價為 85.15 美元。該公司的債務與股本比率為 0.83，流動比率為 0.83，速動比率為 0.63。該公司的 50 日移動平均價格為 79.08 美元，200 日移動平均價格為 72.24 美元。該公司的市值為 989.5 億美元，市盈率為 205.14，市盈增長比率為 0.77，貝塔值為 0.48。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business's revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, sell-side analysts forecast that CVS Health will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）在 10 月 29 日的季度財報中宣佈了其季度收益結果。該藥房運營商報告的每股收益（EPS）為 1.60 美元，超出分析師的共識預期 1.36 美元，超出幅度為 0.24 美元。該公司在本季度的收入為 1028.7 億美元，而市場共識預期為 988.5 億美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司的收入較去年同期增長了 7.8%。去年同期，該公司每股收益為 1.09 美元。CVS Health 已將其 2025 財年的指引設定為 6.550-6.650 EPS。作為一個整體，賣方分析師預測 CVS Health 在當前財年將發佈 5.89 EPS。</p>
</div><h2>Hedge Funds Weigh In On CVS Health</h2>
<div class="lb-trans"><h2>對 CVS Health 的對沖基金看法</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是買入 Novo Nordisk 股票的時機嗎？</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in CVS Health by 0.3% in the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock valued at $4,443,357,000 after purchasing an additional 149,701 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of CVS Health by 5.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,855,845 shares of the pharmacy operator's stock worth $541,903,000 after buying an additional 385,806 shares during the last quarter. Amundi boosted its position in shares of CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator's stock worth $572,665,000 after buying an additional 3,637,943 shares in the last quarter. Wellington Management Group LLP grew its stake in CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator's stock valued at $477,273,000 after acquiring an additional 5,042,816 shares during the last quarter. Finally, Raymond James Financial Inc. increased its holdings in CVS Health by 4.4% during the 2nd quarter. Raymond James Financial Inc. now owns 3,191,584 shares of the pharmacy operator's stock valued at $220,155,000 after acquiring an additional 133,875 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買入和賣出了該公司的股票。道富銀行在第三季度將其在 CVS Health 的持股增加了 0.3%。道富銀行目前擁有 58,938,286 股該藥房運營商的股票，價值 4,443,357,000 美元，此前在上個季度購買了 149,701 股。Ameriprise Financial Inc.在第二季度將其在 CVS Health 的持股增加了 5.2%。Ameriprise Financial Inc.目前擁有 7,855,845 股該藥房運營商的股票，價值 541,903,000 美元，此前在上個季度購買了 385,806 股。阿穆迪在第三季度將其在 CVS Health 的持股增加了 95.3%。阿穆迪目前擁有 7,453,980 股該藥房運營商的股票，價值 572,665,000 美元，此前在上個季度購買了 3,637,943 股。威靈頓管理集團在第三季度將其在 CVS Health 的持股增加了 391.6%。威靈頓管理集團目前擁有 6,330,717 股該藥房運營商的股票，價值 477,273,000 美元，此前在上個季度購買了 5,042,816 股。最後，雷蒙德·詹姆斯金融在第二季度將其在 CVS Health 的持股增加了 4.4%。雷蒙德·詹姆斯金融目前擁有 3,191,584 股該藥房運營商的股票，價值 220,155,000 美元，此前在上個季度購買了 133,875 股。80.66% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What is MarketRank™? How to Use it</li>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 CVS Health</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>降息使這三隻收入 ETF 比以往更具吸引力</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

CVS Health（紐約證券交易所代碼：CVS）發佈 2025 財年收益指引